| Hassan Ahmed, MD | |
|
515 W Mayfield Rd Ste 301, Arlington, TX 76014-2085 | |
| (682) 306-6777 | |
| (682) 306-6776 |
| Full Name | Hassan Ahmed |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 22 Years |
| Location | 515 W Mayfield Rd Ste 301, Arlington, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295020386 | NPI | - | NPPES |
| 200806150A | Medicaid | OK | |
| 340907004 | Medicaid | TX | |
| 74753045 | Medicaid | NM | |
| 340907003 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | Q0857 (Texas) | Secondary |
| 2086X0206X | Surgery - Surgical Oncology | Q0857 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Christus Mother Frances Hospital | Tyler, TX | Hospital |
| Medical City Plano | Plano, TX | Hospital |
| Medical City Dallas Hospital | Dallas, TX | Hospital |
| Medical City Denton | Denton, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Christus Trinity Clinic | 3072426741 | 1227 |
| Surgery Associates Of Ntx Pllc | 7810219375 | 15 |
News Archive
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
More than 50 million U.S. adults have arthritis. Many experience severe joint pain and, likely because of their pain, don't do much exercising if at all.
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the Israeli Office of the Chief Scientist (OCS) has approved a 2011 grant to PROLOR's Israeli-based R&D subsidiary for the company's development program for hGH-CTP, its long-acting version of human growth hormone.
Genomic screening of more than 50,000 people shows that more than 80% of those who carry an identifiable genetic risk for breast, ovarian, prostate, and pancreatic cancer don't know it despite frequent interaction with the healthcare system.
Taking medications as prescribed is challenging for many patients, and following doctors' orders regarding medication often varies over time and among different patients. The consequences of failing to follow the prescribed medication regimen range from mild to life-threatening, depending on the medication and the illness or condition being treated.
› Verified 4 days ago
| Entity Name | Christus Trinity Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285684225 PECOS PAC ID: 3072426741 Enrollment ID: O20031204001091 |
News Archive
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
More than 50 million U.S. adults have arthritis. Many experience severe joint pain and, likely because of their pain, don't do much exercising if at all.
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the Israeli Office of the Chief Scientist (OCS) has approved a 2011 grant to PROLOR's Israeli-based R&D subsidiary for the company's development program for hGH-CTP, its long-acting version of human growth hormone.
Genomic screening of more than 50,000 people shows that more than 80% of those who carry an identifiable genetic risk for breast, ovarian, prostate, and pancreatic cancer don't know it despite frequent interaction with the healthcare system.
Taking medications as prescribed is challenging for many patients, and following doctors' orders regarding medication often varies over time and among different patients. The consequences of failing to follow the prescribed medication regimen range from mild to life-threatening, depending on the medication and the illness or condition being treated.
› Verified 4 days ago
| Entity Name | Texas Tech University Health Sciences Center Amarillo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013942150 PECOS PAC ID: 9234037847 Enrollment ID: O20031220000051 |
News Archive
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
More than 50 million U.S. adults have arthritis. Many experience severe joint pain and, likely because of their pain, don't do much exercising if at all.
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the Israeli Office of the Chief Scientist (OCS) has approved a 2011 grant to PROLOR's Israeli-based R&D subsidiary for the company's development program for hGH-CTP, its long-acting version of human growth hormone.
Genomic screening of more than 50,000 people shows that more than 80% of those who carry an identifiable genetic risk for breast, ovarian, prostate, and pancreatic cancer don't know it despite frequent interaction with the healthcare system.
Taking medications as prescribed is challenging for many patients, and following doctors' orders regarding medication often varies over time and among different patients. The consequences of failing to follow the prescribed medication regimen range from mild to life-threatening, depending on the medication and the illness or condition being treated.
› Verified 4 days ago
| Entity Name | Concord Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083630610 PECOS PAC ID: 0446296818 Enrollment ID: O20050707000531 |
News Archive
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
More than 50 million U.S. adults have arthritis. Many experience severe joint pain and, likely because of their pain, don't do much exercising if at all.
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the Israeli Office of the Chief Scientist (OCS) has approved a 2011 grant to PROLOR's Israeli-based R&D subsidiary for the company's development program for hGH-CTP, its long-acting version of human growth hormone.
Genomic screening of more than 50,000 people shows that more than 80% of those who carry an identifiable genetic risk for breast, ovarian, prostate, and pancreatic cancer don't know it despite frequent interaction with the healthcare system.
Taking medications as prescribed is challenging for many patients, and following doctors' orders regarding medication often varies over time and among different patients. The consequences of failing to follow the prescribed medication regimen range from mild to life-threatening, depending on the medication and the illness or condition being treated.
› Verified 4 days ago
| Entity Name | Concord Medical Group Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750790762 PECOS PAC ID: 7810117223 Enrollment ID: O20141007002567 |
News Archive
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
More than 50 million U.S. adults have arthritis. Many experience severe joint pain and, likely because of their pain, don't do much exercising if at all.
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the Israeli Office of the Chief Scientist (OCS) has approved a 2011 grant to PROLOR's Israeli-based R&D subsidiary for the company's development program for hGH-CTP, its long-acting version of human growth hormone.
Genomic screening of more than 50,000 people shows that more than 80% of those who carry an identifiable genetic risk for breast, ovarian, prostate, and pancreatic cancer don't know it despite frequent interaction with the healthcare system.
Taking medications as prescribed is challenging for many patients, and following doctors' orders regarding medication often varies over time and among different patients. The consequences of failing to follow the prescribed medication regimen range from mild to life-threatening, depending on the medication and the illness or condition being treated.
› Verified 4 days ago
| Entity Name | Surgery Associates Of Ntx Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134522691 PECOS PAC ID: 7810219375 Enrollment ID: O20141211001538 |
News Archive
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
More than 50 million U.S. adults have arthritis. Many experience severe joint pain and, likely because of their pain, don't do much exercising if at all.
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the Israeli Office of the Chief Scientist (OCS) has approved a 2011 grant to PROLOR's Israeli-based R&D subsidiary for the company's development program for hGH-CTP, its long-acting version of human growth hormone.
Genomic screening of more than 50,000 people shows that more than 80% of those who carry an identifiable genetic risk for breast, ovarian, prostate, and pancreatic cancer don't know it despite frequent interaction with the healthcare system.
Taking medications as prescribed is challenging for many patients, and following doctors' orders regarding medication often varies over time and among different patients. The consequences of failing to follow the prescribed medication regimen range from mild to life-threatening, depending on the medication and the illness or condition being treated.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hassan Ahmed, MD 515 W Mayfield Rd Ste 301, Arlington, TX 76014-2085 Ph: (682) 306-6777 | Hassan Ahmed, MD 515 W Mayfield Rd Ste 301, Arlington, TX 76014-2085 Ph: (682) 306-6777 |
News Archive
Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
More than 50 million U.S. adults have arthritis. Many experience severe joint pain and, likely because of their pain, don't do much exercising if at all.
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the Israeli Office of the Chief Scientist (OCS) has approved a 2011 grant to PROLOR's Israeli-based R&D subsidiary for the company's development program for hGH-CTP, its long-acting version of human growth hormone.
Genomic screening of more than 50,000 people shows that more than 80% of those who carry an identifiable genetic risk for breast, ovarian, prostate, and pancreatic cancer don't know it despite frequent interaction with the healthcare system.
Taking medications as prescribed is challenging for many patients, and following doctors' orders regarding medication often varies over time and among different patients. The consequences of failing to follow the prescribed medication regimen range from mild to life-threatening, depending on the medication and the illness or condition being treated.
› Verified 4 days ago
Dr. Angela Escobar Seda, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 906 W Randol Mill Rd Ste 200, Arlington, TX 76012 Phone: 817-261-4906 Fax: 817-261-5837 | |
Charles R. Mathis, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1001 N Waldrop Dr Ste 811, Arlington, TX 76012 Phone: 817-801-3092 Fax: 817-801-3110 | |
Dr. Kory Jones, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 515 W Mayfield Rd Ste 101, Arlington, TX 76014 Phone: 817-664-4400 Fax: 817-664-4414 | |
Elizabeth Hernandez Cardona, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 1000 N Davis Dr Ste B, Arlington, TX 76012 Phone: 817-342-0232 Fax: 817-275-1401 | |
Dr. Brandon Levy, MD Surgery Medicare: Medicare Enrolled Practice Location: 515 W Mayfield Rd Ste 118, Arlington, TX 76014 Phone: 877-314-8990 Fax: 833-794-3342 | |
Dr. Michelle Moriah Hagopian, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3301 Matlock Rd, Arlington, TX 76015 Phone: 917-334-2659 | |
Siddhartha Rath, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3215 Omega Dr, Arlington, TX 76014 Phone: 817-466-7400 |